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Estrogen is Involved in Expression of Angiotensin Converting Enzyme
Yasuhiro Yamanouchi (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 
350-0495, Japan)
Estrogen(E2) regulates the components of the renin-angiotensin system(RAS).Regulation of angiotensinogen 
(ATG) gene expression by estrogen is well known, however, the effects of estrogen on angiotensin converting 
enzyme (ACE) remains unclear. Methods: (Study 1);Thirty female spontaneously hypertensive rats (SHR) at the 
age of 14 weeks were divided into 3 groups. C group: control group, OVX group: ovariectomy group, OVE group: 
ovariectomy group with supplementation of E2(transplant of a 1.5 mg/pellet/90 days sabcutaneously). Systolic 
blood pressure was measured every 2 weeks until the end of the experiment (22 weeks of age). At the end of 
the experiment, blood was taken for measurements of angiotensin I (AngI), angiotensin II(AngII), plasma renin 
activity (PRA), angiotensin converting enzyme (ACE) activity and 17 beta estradiol (E2). Expression of mRNA 
of ACE in the kidney was examined by using RNase protection assay (RPA).(Study 2); Incubation with E2(10
－9, 
10－8, 10－7 M) or Ang II (10－8, 10－7, 10－6 M) in human umbilical vein endothelial cell (HUVEC) was carried out, 
and expression of ACE mRNA in HUVEC was measured by RPA method. In addition, incubation with both 
E2(10
－7 M) and tamoxifen (10－6 M) in HUVEC was carried out, and expression of ACE mRNA in HUVEC was 
measured in a similar way. Results: (Study 1); In rats in the OVX group, Ang II and ACE activity were increased 
significantly compared to those in the C group. In contrast, in rats in the OVE group, Ang II and ACE activity 
were decreased significantly compared to those in the OVX group. Expression of ACE mRNA in kidneys was 
increased in the OVX group, and was reduced in OVE group. (Study 2); In HUVEC treated with E2, expression 
of ACE mRNA was decreased dose-dependently and maximally suppressed at 12 h. In HUVEC treated with E2, 
the suppression of the expression of ACE mRNA was completely protected by the combined administration 
of Tamoxifen. In HUVEC treated with Ang II, expression of ACE mRNA was increased dose-dependently and 
maximally increased at 3 h.Conclusion: E2 suppresses expression of ACE mRNA, and inhibits ACE activity in 
vivo and in vitro. In contract, AngII promotes production of ACE in vitro. We conclude that E2 is an important 
regulator of ACE mRNA expression, resulting in the role of the master of the renin-angiotensin system in women.
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placebo pellet（Innovative Research of America, FL, 
USA）を移植した．OVE群は，左右の腰背部より開
腹し左右の卵巣を摘出，さらに頚背部を切開し皮下に
1.5 mg/pellet/90 daysのE2を含有するpellet（E2-pellet, 






















AngI および AngII の測定は，RIA2 抗体法（トレー








































Dextran treated FBS（Hyclone, UT, USA）（最終濃度：


















また internal controlとして，Gallagherらの報告 16）を






total RNA（0.5μg ）を templateとし，high fidelity RNA 
PCR kit（takara， 東京）を用い，Reverse Transcription-
Polymerase Chain Reaction（以下RT-PCRと略す）を
行 っ た．RT-PCRは，high fidelity RNA PCR kitの プ
ロトコールに準じて行った．なお，PCRの条件は




ランプ（BLAK-RAY LAMP （LONGWAVE UV-365NM） 
：ULTRAVIOLET，UVL-21，CA, USA）下で，目的の
サイズのバンドを切り出し，チューブ（Non-Sterile 












LA培地（Tryptone peptone（BECTON DICKINSON, 












sequencer（BECHMAN COULTER, CA, USA）を用い
て確認した．
RNase protection assay（RPA）
Riboprobeは，SP 6 polymerase（Roche, IN, USA）




ACE cDNA 断片を含む pCRⅡ TOPO プラスミド
（pCRⅡ TOPO, invi trogen,  CA,  USA）を PvuⅡ
（TAKARA，東京）によって切断して，ラットの直鎖











した．サンプルの total RNA：10μg と，ACE：5×105
cpmおよびEF1α：5×105 cpmのriboprobeをハイブ
リバッファー（40 mM PIPES（pH6.4）（和光，東京），






MU，USA），300 mM NaCl，5 mM EDTA（pH8.0））
を加え30℃，60分間で処理し，その後SDS-proteinase




（95 % Formamide， 5 mM EDTA（pH8.0），0.025 % 
















析は，血圧についてはTwo-way analysis of variance
を用いて群間比較を行った後，Scheffe's F testを
行った．また血中ホルモンの変化，ACE mRNAの変














意に増加した（ 20週齢：Control vs．OVX：167±3 vs．175
±3 mmHg，p＜0.05）， （22週齢：Control vs．OVX ：171±
4 vs． 181±5 mmHg，p＜0.05）．またOVE群では血圧の増
加はほぼC群と同レベルであり，E2の補充により血圧の
上昇が抑制された（ 20週齢：OVX vs．OVE：175±3 vs．166
±3.5 mmHg，p＜0.05 ），（22週齢： OVX vs．OVE ：181±
5 vs． 168±3.5 mmHg，p＜0.05 ）．（Fig.  1）
血中生理活性物質の変化
20週齢時の断頭採血によるE2濃度は対照群（n＝10， 
20.75±1.8 pg/ml ），OVX群（n＝10，5.2±0.7 pg/ml，p＜0.01







群（n＝8） vs． OVX群（n＝8） ：9.3±3.3 vs． 24.7±3.4
IU/l/37℃，p＜0.01），さらにE2補充により，その上昇は
有意に抑制された（OVX群（n＝8） vs. OVE群（n＝5）： 
24.7±3.4 vs. 3.7±3.3 IU/l/37℃，p＜0.01）．AngIの 変
化はC群とOVX群の2群間では有意な差を認めなかっ
たが（C群（n＝10） vs. OVX群（n＝10）： 4480±1636





45， vs． 620±51 pg/ml，p＜0.05），E2補充により有意に
減少した（OVX 群（n＝8）vs． OVE 群（n＝8）：620±51




（Control vs. OVX： 0.91±0.33 vs． 1.00， p＜0.05），
さらにE2補充により，その上昇は著明に抑制された





















Fig. 1. Effect of ovariectomy (OVX) and OVX ＋ 17β -estradiol 
(OVE) on systolic blood pressure in SHR. Values are shown 
as the means±S.E.M. except highest and lowest SBP. Light 
rhombic:control group, closed squares:OVX group, high light 
triangles:OVE group. (＊p＜0.05 vs. control, #p＜0.05 vs. OVE)
Table 1.Effect of ovariectomy (OVX) and OVX ＋17β-estradiol 
(OVE) on plasma 17β -estradiol, plasma renin activity (PRA), 
angiotensin converting enzyme (ACE), angiotensin I (Ang I) 
and angiotensin II (Ang II) in SHR at 22weeks of age. (No.) 
indicates the number of samples. Values are shown as the 
means±S.E.M.. (＊p＜0.01 vs. control, #p＜0.01 vs. OVX)
Fig. 2. Effect of ovariectomy (OVX) and OVX ＋17β-estradiol 
(OVE) on the expression of ACE mRNA in SHR. Values are shown as 
the means±S.E.M.. Light bar:control group, closed bar:OVX group, 
high light bar:OVE group. (＊p＜ 0.05 vs. control, #p＜ 0.01 vs. OVX)
Fig. 3. Effect of 17β -estradiol on the expression of ACE mRNA 
in HUVEC. Values are shown as the means±S.E.M. for 5 times 
examinations. (＊p＜0.05, ＊＊p＜0.01 vs. pretreatment value) 
Fig. 4. Effect of 17β -estradiol on the expression of ACE mRNA 
in HUVEC. Values are shown as the means±S.E.M. for 5 times 





























































Fig. 5. Ef fect of 17β -estradiol and Tamoxifen on the 
expression of ACE mRNA in HUVEC. Values are shown as 
the means±S.E.M. for 5 times examinations. (＊p＜0.05 vs. 
pretreatment value)
Fig. 6. Effect of Angiotensin II on the expression of ACE 
mRNA in HUVEC. Values are shown as the means±S.E.M. 
for 5 times examinations. (＊p＜0.05 vs. pretreatment value)
Fig. 7. Effect of Angiotensin II on the expression of ACE 
mRNA in. Values are shown as the means±S.E.M. for 5 times 










































































受容体を介し PRA を抑制するとの報告があるが 66），
ACEに関しての報告はほとんど認められていない．
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